Cargando…

Evaluation of the PIK3 pathway in peripheral T‐cell lymphoma and NK/T‐cell lymphoma

Peripheral T‐cell lymphomas (PTCL) and natural killer (NK)/T‐cell lymphomas (NKTCL) are a heterogeneous group of aggressive malignancies with dismal outcomes and limited treatment options. While the phosphatidylinositol 3‐kinase (PIK3) pathway has been shown to be highly activated in many B‐cell lym...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Dachuan, Song, Tammy Linlin, Nairismägi, Maarja‐Liisa, Laurensia, Yurike, Pang, Wan‐Lu, Zhe, Daryl Cheah Ming, Wong, Esther Kam Yin, Wijaya, Giovani Giovani‐Clarest, Tan, Jing, Tan, Sze Huey, Lim, Jing‐Quan, Chia, Burton Kuan Hui, Chan, Jason Yongsheng, Tang, Tiffany Pooi Ling, Somasundaram, Nagavalli, Cheng, Chee Leong, Politz, Oliver, Liu, Ningshu, Lim, Soon Thye, Ong, Choon Kiat
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Haematological Malignancy ‐ Clinical
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7322801/ https://www.ncbi.nlm.nih.gov/pubmed/32004387 http://dx.doi.org/10.1111/bjh.16435

Ejemplares similares

An open‐label phase 2 trial of entospletinib in indolent non‐Hodgkin lymphoma and mantle cell lymphoma
por: Andorsky, David J., et al.
Publicado: (2018)

A clinicohaematological prognostic model for nasal-type natural killer/T-cell lymphoma: A multicenter study
por: Tan, Khee Ming, et al.
Publicado: (2019)

A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma
por: Ogura, Michinori, et al.
Publicado: (2014)

Pathogenesis and biomarkers of natural killer T cell lymphoma (NKTL)
por: Somasundaram, Nagavalli, et al.
Publicado: (2019)

SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma – a Nordic Lymphoma Group study
por: Nordström, Lena, et al.
Publicado: (2014)

The impact of SOCS1 mutations in diffuse large B‐cell lymphoma
por: Mellert, Kevin, et al.
Publicado: (2019)

Diagnostic markers for CNS lymphoma in blood and cerebrospinal fluid: a systematic review
por: van Westrhenen, Anouk, et al.
Publicado: (2018)

Early‐stage Hodgkin lymphoma in the modern era: simulation modelling to delineate long‐term patient outcomes
por: Parsons, Susan K., et al.
Publicado: (2018)

Patient and physician preferences for first‐line treatment of classical Hodgkin lymphoma in Germany, France and the United Kingdom
por: Bröckelmann, Paul J., et al.
Publicado: (2018)

Timing of autologous stem cell transplantation from last chemotherapy affects lymphocyte collection and survival in non-Hodgkin lymphoma
por: Holtan, Shernan G, et al.
Publicado: (2006)

Improved outcome of patients with relapsed/refractory Hodgkin lymphoma with a new fotemustine‐based high‐dose chemotherapy regimen
por: Musso, Maurizio, et al.
Publicado: (2015)

Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma
por: Feldman, Tatyana, et al.
Publicado: (2014)

A randomized, double‐blind trial of pegfilgrastim versus filgrastim for the management of neutropenia during CHASE(R) chemotherapy for malignant lymphoma
por: Kubo, Kohmei, et al.
Publicado: (2016)

Peripheral T cell lymphoma, not otherwise specified (PTCL‐NOS). A new prognostic model developed by the International T cell Project Network
por: Federico, Massimo, et al.
Publicado: (2018)

Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma
por: Oflazoglu, Ezogelin, et al.
Publicado: (2008)

Prospective subgroup analyses of the randomized MCL‐002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma
por: Arcaini, Luca, et al.
Publicado: (2017)

Combination lenalidomide‐rituximab immunotherapy activates anti‐tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma
por: Chiu, Hsiling, et al.
Publicado: (2019)

Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study
por: Pettengell, Ruth, et al.
Publicado: (2008)

Dose‐intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T‐cell leukaemia‐lymphoma: a randomized phase II study
por: Ishida, Takashi, et al.
Publicado: (2015)

Impact of novel therapies for mantle cell lymphoma in the real world setting: a report from the UK's Haematological Malignancy Research Network (HMRN)
por: Smith, Alexandra, et al.
Publicado: (2018)

Transformed mucosa‐associated lymphoid tissue lymphomas: A single institution retrospective study including polymerase chain reaction‐based clonality analysis
por: Kiesewetter, Barbara, et al.
Publicado: (2019)

Diagnosis of intravascular large B cell lymphoma: novel insights into clinicopathological features from 42 patients at a single institution over 20 years
por: Matsue, Kosei, et al.
Publicado: (2019)

Monotherapy with pixantrone in histologically confirmed relapsed or refractory aggressive B‐cell non‐Hodgkin lymphoma: post‐hoc analyses from a phase III trial
por: Pettengell, Ruth, et al.
Publicado: (2016)

Whole exome sequencing identifies recessive germline mutations in FAM160A1 in familial NK/T cell lymphoma
por: Chan, Jason Yongsheng, et al.
Publicado: (2018)

Lenalidomide plus rituximab (R(2)) in previously untreated marginal zone lymphoma: subgroup analysis and long‐term follow‐up of an open‐label phase 2 trial
por: Becnel, Melody R., et al.
Publicado: (2019)

Longer‐term follow‐up and outcome by tumour cell proliferation rate (Ki‐67) in patients with relapsed/refractory mantle cell lymphoma treated with lenalidomide on MCL‐001(EMERGE) pivotal trial
por: Goy, Andre, et al.
Publicado: (2015)

A phase 1/2 trial of ublituximab, a novel anti‐CD20 monoclonal antibody, in patients with B‐cell non‐Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab
por: Sawas, Ahmed, et al.
Publicado: (2017)

Biweekly rituximab, cyclophosphamide, vincristine, non-pegylated liposome-encapsulated doxorubicin and prednisone (R-COMP-14) in elderly patients with poor-risk diffuse large B-cell lymphoma and moderate to high ‘life threat’ impact cardiopathy
por: Corazzelli, Gaetano, et al.
Publicado: (2011)

Late recurrence of lymphoid malignancies after initial treatment for Hodgkin lymphoma – A study from the Danish Lymphoma Registry
por: Andersen, Maja Dam, et al.
Publicado: (2022)

Lymphoplasmacytic lymphoma and marginal zone lymphoma involving bone marrow: A diagnostic dilemma. Useful clinicopathological features to accurate the diagnosis
por: García‐Abellás, Patricia, et al.
Publicado: (2022)

Clinical characteristics and outcomes among 2347 patients aged ≥85 years with major lymphoma subtypes: a Nordic Lymphoma Group study
por: Wästerlid, Tove, et al.
Publicado: (2020)

Characteristics and prognosis of distant metastasis after primary treatment for early‐stage extranodal nasal‐type natural killer/T‐cell lymphoma from the China Lymphoma Collaborative Group database
por: Zheng, Xuan, et al.
Publicado: (2022)

Checkpoint CD47 expression in classical Hodgkin lymphoma
por: Gholiha, Alex Reza, et al.
Publicado: (2022)

A multicenter, real‐world analysis of primary central nervous system lymphoma in those with and without human immunodeficiency virus
por: Dittus, Christopher, et al.
Publicado: (2022)

Phase Ib study of avadomide (CC‐122) in combination with rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma and follicular lymphoma
por: Nastoupil, Loretta J., et al.
Publicado: (2022)

Primary central nervous system lymphoma: Inter‐compartmental progression
por: Raval, Vishal, et al.
Publicado: (2022)

The combination of ibrutinib and rituximab demonstrates activity in first‐line follicular lymphoma
por: Fowler, Nathan H., et al.
Publicado: (2020)

Prevalence and the impact of hypogammaglobulinemia in newly diagnosed chronic lymphocytic lymphoma patients
por: Singh, Namrata, et al.
Publicado: (2020)

Targetable alterations in primary extranodal diffuse large B‐cell lymphoma
por: Weissinger, Stephanie E., et al.
Publicado: (2022)

Clinical significance of TP53 mutations in adult T‐cell leukemia/lymphoma
por: Sakamoto, Yuma, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_v3vr953e9vq4idmnvp0b1c2dmi